Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Investigative Ophthalmology and Visual Science

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1167/IOVS.03-0567PMID 15277487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].

  2008cited by this paper
• Multivariate Statistical Methods

  2005cited by this paper
• Effect of ischaemia and reperfusion on the extra- and intracellular distribution of glutamate, glutamine, aspartate and GABA in the rat hippocampus, with a note on the effect of the sodium channel blocker BW1003C87

  2004cited by this paper
• Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.

  2004influential reference
• Laser Doppler Flowmetry Study of Systemic Vasoconstriction after Topical 2.5% Phenylephrine Eye Drops

  2004cited by this paper
• Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy.

  2003cited by this paper
• A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

  2002cited by this paper
• Visual field defects and neural losses from experimental glaucoma.

  2002cited by this paper
• Measurement of amino acid levels in the vitreous humor of rats after chronic intraocular pressure elevation or optic nerve transection.

  2002cited by this paper
• Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat.

  2002cited by this paper
• The impact of ocular blood flow in glaucoma.

  2002cited by this paper
• Vitreal glutamate concentration in monkeys with experimental glaucoma.

  2002cited by this paper
• Effects of APB, PDA, and TTX on ERG responses recorded using both multifocal and conventional methods in monkey

  2002cited by this paper
• Neuroprotective Effect of Memantine in Different Retinal Injury Models in Rats

  2002cited by this paper
• Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

  2002cited by this paper
• Characterization of retinal injury using ERG measures obtained with both conventional and multifocal methods in chronic ocular hypertensive primates.

  2001cited by this paper
• Selective excitotoxic degeneration of adult pig retinal ganglion cells in vitro.

  2001cited by this paper
• Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats.

  2001cited by this paper
• Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey.

  2001cited by this paper
• Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons.

  2000cited by this paper
• Concordance Between Results of Optic Disc Tomography and High‐pass Resolution Perimetry in Glaucoma

  2000cited by this paper
• Topographic sector-by-sector analysis of the optic nerve head by HRT and correlation with frank glaucoma perimetric indices.

  2000cited by this paper
• Effects of experimental glaucoma in macaques on the multifocal ERG

  2000cited by this paper
• Protection of ganglion cells in experimental glaucoma by retinal laser photocoagulation.

  2000cited by this paper
• Spatial relationship of motion automated perimetry and optic disc topography in patients with glaucomatous optic neuropathy.

  1999cited by this paper
• Relationship between parapapillary atrophy and visual field abnormality in primary open-angle glaucoma.

  1999cited by this paper
• Brain Penetration and In Vivo Recovery of NMDA Receptor Antagonists Amantadine and Memantine: A Quantitative Microdialysis Study

  1999cited by this paper
• Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine)

  1999cited by this paper
• Evidence for a ganglion cell contribution to the primate electroretinogram (ERG): Effects of TTX on the multifocal ERG in macaque

  1999cited by this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999cited by this paper
• Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia

  1999cited by this paper
• The optic nerve head component of the human ERG.

  1999cited by this paper
• Electrophysiological and Histological Measures of Retinal Injury in Chronic Ocular Hypertensive Monkeys

  1999cited by this paper
• Vascular aspects in the pathophysiology of glaucomatous optic neuropathy.

  1999cited by this paper
• Ganglion cell losses underlying visual field defects from experimental glaucoma.

  1999cited by this paper
• Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.

  1999cited by this paper
• Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy.

  1998cited by this paper
• Mapping structural to functional damage in glaucoma with standard automated perimetry and confocal scanning laser ophthalmoscopy.

  1998cited by this paper
• Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells.

  1998cited by this paper
• Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia.

  1998cited by this paper
• Relationship of optic disc topography to optic nerve fiber number in glaucoma.

  1998cited by this paper
• Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism.

  1997cited by this paper
• Correlation of blue-on-yellow visual fields with scanning confocal laser optic disc measurements.

  1997cited by this paper
• Correlation Between the Visual Field Indices and Heidelberg Retina Tomograph Parameters

  1997cited by this paper
• Sector‐Based Analysis of Optic Nerve Head Shape Parameters and Visual Field Indices in Healthy and Glaucomatous Eyes

  1997cited by this paper
• Vitreous body glutamate concentration in dogs with glaucoma.

  1997cited by this paper
• Mapping structural damage of the optic disk to visual field defect in glaucoma.

  1997cited by this paper
• Study of Central Retinal Ganglion Cell Loss in Experimental Glaucoma in Monkey Eyes

  1996cited by this paper
• Disturbances in the distribution of neurotransmitters in the rat retina after ischemia.

  1996cited by this paper
• Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine.

  1996cited by this paper
• Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.

  1996cited by this paper
• Expression of NMDA and High‐affinity Kainate Receptor Subunit mRNAs in the Adult Rat Retina

  1994cited by this paper
• Rapid postmortem changes in the cellular localisation of amino acid transmitters in the retina as assessed by immunocytochemistry.

  1994cited by this paper
• Effects of Ischaemia on Neurotransmitter Release from the Isolated Retina

  1994cited by this paper
• Effect of repetitive imaging on topographic measurements of the optic nerve head.

  1993cited by this paper
• Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

  1993cited by this paper
• Relationship between extracellular neurotransmitter amino acids and energy metabolism during cerebral ischemia in rats monitored by microdialysis and in vivo magnetic resonance spectroscopy.

  1993cited by this paper
• Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture.

  1993cited by this paper
• Glutamate Release in Experimental Ischaemia of the Retina: An Approach Using Microdialysis

  1992cited by this paper
• The field topography of ERG components in man--I. The photopic luminance response.

  1992cited by this paper
• Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

  1992cited by this paper
• Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease

  1992cited by this paper
• Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.

  1992cited by this paper
• Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

  1991cited by this paper
• N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro

  1991cited by this paper
• Changes in Extracellular Concentrations of Glutamate, Aspartate, Glycine, Dopamine, Serotonin, and Dopamine Metabolites After Transient Global Ischemia in the Rabbit Brain

  1991cited by this paper
• A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick

  1990cited by this paper
• Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.

  1989cited by this paper
• Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma.

  1989cited by this paper
• Responses mediated by excitatory amino acid receptors in solitary retinal ganglion cells from rat.

  1988cited by this paper
• Chronic human glaucoma causing selectively greater loss of large optic nerve fibers.

  1988cited by this paper
• Effect of Ischemia on the In Vivo Release of Striatal Dopamine, Glutamate, and γ‐Aminobutyric Acid Studied by Intracerebral Microdialysis

  1988cited by this paper
• Glutamate receptors of ganglion cells in the rabbit retina: evidence for glutamate as a bipolar cell transmitter.

  1988cited by this paper
• Glutamate activates multiple single channel conductances in hippocampal neurons

  1987cited by this paper
• NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones

  1986cited by this paper
• Distribution of metabolism of the potential anti-parkinson drug memantine in the human.

  1980cited by this paper
• Experimental glaucoma in the rhesus monkey.

  1974cited by this paper
• Printed in Great Britain

  1970cited by this paper
• GLUTAMATE—INDUCED RETINAL DEGENERATION IN NEONATAL MICE. ELECTRON MICROSCOPY OF THE ACUTELY EVOLVING LESION

  1969cited by this paper
• STATISTICAL METHODS

  1967cited by this paper
• The toxic effect of sodium L-glutamate on the inner layers of the retina.

  1957cited by this paper

• Synaptic control of retinal ganglion cell survival and axon regeneration

  2026cites this paper
• Medical glaucoma management: what's new on the horizon?

  2025cites this paper
• Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma

  2025cites this paper
• Role of Endocannabinoids in Glaucoma: A Review

  2025cites this paper
• Neuroprotective Activity of Rasayana Formulation and Effect of Shigru Pallava Eye Drops on Intraocular Pressure as an Add-on Therapy Compared to the Standard of Care in Primary Open-Angle Glaucoma: Protocol for an Exploratory, Open-label, Two-arm Randomized Controlled Trial

  2025cites this paper
• Emerging trends in long-acting sustained drug delivery for glaucoma management

  2025cites this paper
• Translational Research and Therapies for Neuroprotection and Regeneration of the Optic Nerve and Retina: A Narrative Review

  2024cites this paper
• Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments.

  2024cites this paper
• Mechanosensitive ion channels in glaucoma pathophysiology.

  2024cites this paper
• Activation of retinal glial cells contributes to the degeneration of ganglion cells in experimental glaucoma.

  2023cites this paper
• Glaucoma: neuroprotection with NAD-based therapeutic interventions.

  2023cites this paper
• Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future

  2022cites this paper
• Drug Discovery Strategies for Inherited Retinal Degenerations

  2022cites this paper
• A longitudinal comparison in cynomolgus macaques of the effect of brimonidine on optic nerve neuropathy using diffusion tensor imaging magnetic resonance imaging and spectral domain optical coherence tomography

  2021cites this paper
• Targeting the NLRP3 Inflammasome in Glaucoma

  2021cites this paper
• SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine

  2021cites this paper
• Memantine and its benefits for cancer, cardiovascular and neurological disorders.

  2021cites this paper
• Loss of P2Y1 receptors triggers glaucoma‐like pathology in mice

  2021cites this paper
• Looking into the future: Gene and cell therapies for glaucoma.

  2021cites this paper
• Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases.

  2021cites this paper
• Medikamentöse Therapie des Glaukoms

  2020cites this paper
• Medikamentöse Therapie des Glaukoms

  2020cites this paper
• Advances in Retinal Imaging: Real-Time Imaging of Single Neuronal Cell Apoptosis (DARC)

  2020cites this paper
• Prophylactic anti-glaucoma therapy in dogs with primary glaucoma: A practitioner survey of current medical protocols.

  2020cites this paper
• [Medical Management of Glaucoma].

  2020cites this paper
• Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

  2020cites this paper
• What’s the Future of Glaucoma Diagnosis and Neuroprotection

  2019cites this paper
• Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development

  2019cites this paper
• Intraocular pressure-independent management of normal tension glaucoma.

  2019cites this paper
• Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications

  2019cites this paper
• Effect of NMDA and AMPA/Kainate Receptor Antagonists Against Ethambutol Induced Retinal Toxicity Using Optomotor Response (OMR) in Goldfish

  2019cites this paper
• Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy

  2019cites this paper
• Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine

  2019cites this paper
• Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model.

  2019cites this paper
• The future of canine glaucoma therapy

  2019cites this paper
• Ophthalmic Research Lecture 2018: DARC as a Potential Surrogate Marker

  2019cites this paper
• The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane.

  2019cites this paper
• DARC as a potential surrogate marker

  2019cites this paper
• Annexins in Glaucoma

  2018cites this paper
• Retinal Neuroprotection: Overcoming the Translational Roadblocks.

  2018cites this paper
• Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.

  2018cites this paper
• Therapeutic potential of valproic acid in advanced glaucoma: A pilot study

  2018cites this paper
• Neuroprotection in Glaucoma: Animal Models and Clinical Trials.

  2017cites this paper
• Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye.

  2017cites this paper
• European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and optionsSupported by the EGS Foundation

  2017cites this paper
• Efferent influences on the bioelectrical activity of the retina in primates

  2017cites this paper
• Chapter 9 Neuroprotection in Glaucoma

  2017cites this paper
• Dock3-NMDA receptor interaction as a target for glaucoma therapy.

  2017cites this paper
• Protecting retinal ganglion cells

  2017cites this paper
• Pharmacologic Therapy of Ocular Disease

  2017cites this paper
• Effect of memantine: A NMDA receptor blocker, on ethambutol-induced retinal injury.

  2016cites this paper
• Normal-tension glaucoma: an update.

  2016cites this paper
• Ocular Hypotensives and Neuroprotectants in Glaucoma

  2016cites this paper
• Treatment of Glaucoma with or without Medications Lowering Intraocular Pressure: Options and Relevant General Health Issues

  2016cites this paper
• Understanding Glaucomatous Optic Neuropathy: The Synergy Between Clinical Observation and Investigation.

  2016cites this paper
• Translational Pharmacology in Glaucoma Neuroprotection.

  2016cites this paper
• INTRAOCULAR SILICONE BALL IMPLANTATION AFTER EVISCERATION IN A SLOW LORIS (NYCTICEBUS COUCANG)

  2016cites this paper
• Intravitreal memantine retinal toxicity in rabbits.

  2016cites this paper
• Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electroretinogram Amplitude, and Foveal Sensitivity

  2016cites this paper
• Intravitreal memantine retinal toxicity in rabbits.

  2016cites this paper
• Neuroprotection and Retinal Diseases.

  2016cites this paper
• Primary open-angle glaucoma

  2016cites this paper
• New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system.

  2016cites this paper
• Neuroprotective Strategies in Glaucoma.

  2016cites this paper
• Present and New Treatment Strategies in the Management of Glaucoma

  2015cites this paper
• 61 – Neuroprotection and Neurorepair

  2015cites this paper
• The non-human primate experimental glaucoma model.

  2015cites this paper
• Neuroprotective therapies for glaucoma

  2015cites this paper
• α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.

  2015cites this paper
• In vivo imaging methods to assess glaucomatous optic neuropathy.

  2015cites this paper
• Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.

  2015cites this paper
• A framework to explore the visual brain in glaucoma with lessons from models and man.

  2015cites this paper
• Role of Reactive Gliosis and Neuroinflammation in Experimental Glaucoma

  2015cites this paper
• Increased Mitochondrial Fission and Volume Density by Blocking Glutamate Excitotoxicity Protect Glaucomatous Optic Nerve Head Astrocytes

  2014cites this paper
• Glutamate and Neurodegeneration in the Retina

  2014cites this paper
• The relationship of TP53 and GRIN2B gene polymorphisms with risk of occurrence and progression of primary open-angle glaucoma in a Polish population.

  2014cites this paper
• Effect of the Aβ Aggregation Modulator MRZ-99030 on Retinal Damage in an Animal Model of Glaucoma

  2014cites this paper
• Presynaptic Inhibition by α2 Receptor/Adenylate Cyclase/PDE4 Complex at Retinal Rod Bipolar Synapse

  2014cites this paper
• Vitreous Pharmacokinetics and Bioavailability of Memantine After Subtenon, Intravenous, and Intravitreal Administration in Rabbits

  2014cites this paper
• New directions in the treatment of normal tension glaucoma

  2014cites this paper
• The Transient Receptor Potential Vanilloid-1 Channel and Neuronal Survival in Degenerative Disease

  2014cites this paper
• Neuroprotection in glaucoma: current and emerging approaches

  2014cites this paper
• Hyperbaric pressure and increased susceptibility to glutamate toxicity in retinal ganglion cells in vitro

  2014cites this paper
• Microcystic Changes in the Retinal Internal Nuclear Layer Associated with Optic Atrophy: A Prospective Study

  2014cites this paper
• Electroretinogram and Visual-Evoked Potential Assessment of Retinal and Central Visual Function in a Rat Ocular Hypertension Model of Glaucoma

  2014cites this paper
• Central nervous system changes in glaucoma.

  2013cites this paper
• The East London glaucoma prediction score: web-based validation of glaucoma risk screening tool.

  2013cites this paper
• Neuroprotection in Glaucoma

  2013cites this paper
• Autocrine and paracrine interactions and neuroprotection in glaucoma

  2013cites this paper
• Strategies for Neuroprotection in Glaucoma

  2013cites this paper
• Challenges in the development of glaucoma neuroprotection therapy

  2013cites this paper
• Using the Electroretinogram to Understand How Intraocular Pressure Elevation Affects the Rat Retina

  2013cites this paper
• Leptin as a neuroprotective agent in glaucoma.

  2013cites this paper
• Farmacocinética, biodisponibilidad y tolerancia ocular de memantina en conejos: Aportaciones al análisis de una nueva formulación oftálmica a base de nanopartículas

  2013cites this paper
• Impairment of Neuronal Glutamate Uptake and Modulation of the Glutamate Transporter GLT-1 Induced by Retinal Ischemia

  2013cites this paper
• A case for neuroprotection in ophthalmology: developments in translational research.

  2013cites this paper
• Functional protective effects of long-term memantine treatment in the DBA/2J mouse

  2013cites this paper
• Does autoimmunity play a part in the pathogenesis of glaucoma?

  2013cites this paper
• Enhanced Expression of NR2B Subunits of NMDA Receptors in the Inherited Glaucomatous DBA/2J Mouse Retina

  2013cites this paper
• Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy?

  2013cites this paper